Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/14/23
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/07/23
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023GlobeNewsWire • 10/31/23
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)GlobeNewsWire • 10/20/23
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1GlobeNewsWire • 10/16/23
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities ConferenceGlobeNewsWire • 10/05/23
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian NationsGlobeNewsWire • 09/06/23
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/14/23
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/08/23
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023GlobeNewsWire • 08/03/23
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023GlobeNewsWire • 08/02/23
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023GlobeNewsWire • 07/19/23
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in AdultsGlobeNewsWire • 07/11/23
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023GlobeNewsWire • 07/03/23
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United StatesGlobeNewsWire • 06/29/23
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial ProgramGlobeNewsWire • 06/15/23
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsGlobeNewsWire • 06/13/23
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/22/23